Cargando…

The future of affordable cancer immunotherapy

The treatment of cancer was revolutionized within the last two decades by utilizing the mechanism of the immune system against malignant tissue in so-called cancer immunotherapy. Two main developments boosted cancer immunotherapy: 1) the use of checkpoint inhibitors, which are characterized by a rel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaft, Niels, Dörrie, Jan, Schuler, Gerold, Schuler-Thurner, Beatrice, Sallam, Husam, Klein, Shiri, Eisenberg, Galit, Frankenburg, Shoshana, Lotem, Michal, Khatib, Areej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509759/ https://www.ncbi.nlm.nih.gov/pubmed/37736099 http://dx.doi.org/10.3389/fimmu.2023.1248867

Ejemplares similares

Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update
por: Dörrie, Jan, et al.
Publicado: (2020)

Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
por: Wiesinger, Manuel, et al.
Publicado: (2019)

A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma
por: Koch, Elias A. T., et al.
Publicado: (2022)

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
por: Harrer, Dennis C., et al.
Publicado: (2019)

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
por: Simon, Bianca, et al.
Publicado: (2018)

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
por: Gerer, Kerstin F., et al.
Publicado: (2017)

Just One Position-Independent Lysine Residue Can Direct MelanA into Proteasomal Degradation following N-Terminal Fusion of Ubiquitin
por: Setz, Christian, et al.
Publicado: (2013)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Hoyer, Stefanie, et al.
Publicado: (2021)

Human T Cell Crosstalk Is Induced by Tumor Membrane Transfer
por: Uzana, Ronny, et al.
Publicado: (2015)

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
por: Dörrie, Jan, et al.
Publicado: (2018)

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
por: Harrer, Dennis C., et al.
Publicado: (2017)

NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells
por: Bosch, Naomi C., et al.
Publicado: (2019)

A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells †
por: Bosch, Naomi C., et al.
Publicado: (2021)

Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells
por: Lutz, Manfred B, et al.
Publicado: (2014)

SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
por: Hajaj, Emma, et al.
Publicado: (2020)

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer
por: Simon, Bianca, et al.
Publicado: (2019)

Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study
por: Hadash-Bengad, Reut, et al.
Publicado: (2020)

Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA
por: Boscheinen, Jan B., et al.
Publicado: (2019)

Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA
por: Moreira, Alvaro, et al.
Publicado: (2020)

Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells
por: Hoyer, Stefanie, et al.
Publicado: (2015)

Human Adenovirus-Specific γ/δ and CD8(+) T Cells Generated by T-Cell Receptor Transfection to Treat Adenovirus Infection after Allogeneic Stem Cell Transplantation
por: Dörrie, Jan, et al.
Publicado: (2014)

CARs: Beyond T Cells and T Cell-Derived Signaling Domains
por: Sievers, Nico M., et al.
Publicado: (2020)

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
por: Harrer, Dennis C., et al.
Publicado: (2019)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options
por: Gehrcken, Laura, et al.
Publicado: (2021)

Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases
por: Beenen, Amke C., et al.
Publicado: (2022)

Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells
por: Schuler-Thurner, Beatrice, et al.
Publicado: (2002)

Genomic analysis of a Palestinian family with inherited cancer syndrome: a next-generation sequencing study
por: Fares, Eman, et al.
Publicado: (2023)

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
por: Lotem, Michal, et al.
Publicado: (2016)

Multi-Level Computational Modeling of Anti-Cancer Dendritic Cell Vaccination Utilized to Select Molecular Targets for Therapy Optimization
por: Lai, Xin, et al.
Publicado: (2022)

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
por: Wiesinger, Manuel, et al.
Publicado: (2017)

Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial
por: Voskens, Caroline J, et al.
Publicado: (2021)

Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation
por: Knippertz, Ilka, et al.
Publicado: (2016)

Network- and systems-based re-engineering of dendritic cells with non-coding RNAs for cancer immunotherapy
por: Lai, Xin, et al.
Publicado: (2021)

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Extracellular vesicles from mature dendritic cells (DC) differentiate monocytes into immature DC
por: Schierer, Stefan, et al.
Publicado: (2018)

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
por: Lotem, M, et al.
Publicado: (2004)

Affordable innovation: future directions in pharmaceutical policy
por: Hill, Suzanne R
Publicado: (2015)

Maximising Affordability of Real-Time Colorimetric LAMP Assays
por: Strachan, Simon, et al.
Publicado: (2023)

Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT Cells
por: Shimizu, Kanako, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qcrs6t0m1u6rilsvtqr8vquiaf